Australia · Delayed Price · Currency is AUD Australian Clinical Labs Earnings Call Transcripts
Fiscal Year 2026
-
Underlying profitability and margins improved despite a 1% revenue decline, driven by operational discipline, digitalization, and portfolio optimization. Guidance anticipates H2 market recovery, with ongoing share buybacks and cost mitigation plans for wage increases.
Fiscal Year 2025
-
The AGM highlighted strong financial growth, strategic expansion, and operational improvements, with $44 million returned to shareholders. Despite a second strike on the Remuneration Report, all director re-elections were supported, and a new share buyback was announced.
-
Revenue grew 6.4% to $741.3M with EBIT up 8.7% and strong cash flow, despite market softness and fee cuts. FY 2026 guidance anticipates continued margin discipline, digital billing, and operational efficiencies, with $8M EBIT uplift expected in FY 2027.
-
Revenue grew 9.5% year-over-year to AUD 369 million, with underlying EBIT up 17% and strong cash flow. Guidance for FY25 EBIT is reaffirmed at AUD 65–73 million, with margin improvement expected in H2. Operational efficiency, AI initiatives, and new tests drive future growth.
Fiscal Year 2024
-
The AGM highlighted stable revenue and profit despite a sharp drop in COVID-related income, with operational improvements and a strong balance sheet supporting dividends and a share buyback. Strategic focus includes network expansion, new genetic tests, and ESG initiatives.
-
FY24 saw stable revenue as non-COVID growth offset a sharp COVID revenue decline, with strong cash flow, margin recovery in H2, and a robust balance sheet. FY25 guidance anticipates 4–8% revenue growth, higher EBIT, and continued operational improvements.